Monoclonal anbibodies which bind to tumor rejection antigen...

C - Chemistry – Metallurgy – 07 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C07K 16/30 (2006.01) A61K 38/17 (2006.01) A61K 39/00 (2006.01) C07K 7/08 (2006.01) C07K 14/47 (2006.01) C07K 14/705 (2006.01) C07K 14/82 (2006.01) C07K 16/28 (2006.01) C12N 5/12 (2006.01) C12N 5/20 (2006.01) G01N 33/53 (2006.01) G01N 33/543 (2006.01) G01N 33/574 (2006.01)

Patent

CA 2182369

The invention relates to monoclonal antibodies which specifically bind to the tumor rejection antigen precursor molecule MAGE-1, hybridomas which produce these monoclonal antibodies, and their use. Also described is a recombinant form of MAGE-1, peptides which are useful as immunogens, and immunogenic compositions containing the peptides and an adjuvant.

L'invention concerne des anticorps monoclonaux qui se fixent spécifiquement au précurseur de l'antigène permettant le rejet de tumeurs qu'est MAGE-1. L'invention concerne également des hybridomes qui produisent ces anticorps monoclonaux et leur utilisation. On décrit également une forme de MAGE-1 obtenue par recombinaison, des peptides qui sont utiles en tant qu'immunogènes et des compositions immunogènes contenant les peptides et un adjuvant.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Monoclonal anbibodies which bind to tumor rejection antigen... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Monoclonal anbibodies which bind to tumor rejection antigen..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal anbibodies which bind to tumor rejection antigen... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1816226

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.